Innovative Liquid Biopsy BioFluidica's focus on liquid biopsy technology, combining microfluidics and advanced chemistries, positions it as a key player in non-invasive diagnostic solutions, creating opportunities for collaborations with healthcare providers and diagnostics companies seeking cutting-edge biomarker detection.

Recent Platform Launch The introduction of LiquidScan™ and new prenatal blood screening studies indicate ongoing product development and market expansion efforts, opening doors for sales of associated hardware, reagents, and follow-up services to research institutions and clinical labs.

Strong Funding Support With over $15 million in funding and recent Series B2 financing of $6 million, BioFluidica is well-capitalized to accelerate commercialization, providing opportunities for strategic partnerships, investment, and sales of their innovative testing platforms and devices.

Collaborative Research Partnerships with academic institutions like Wright State University highlight opportunities to leverage research collaborations for co-marketing, joint ventures, and expanding sales channels within the biotech and healthcare sectors.

Growing Market Focus Recent activities targeting prenatal screening and COVID-19 testing indicate a diverse application base, suggesting potential sales opportunities across prenatal care providers, diagnostic labs, and pandemic response markets seeking reliable biomarker solutions.